Premium
A multicentre phase II clinical experience with the novel aza‐epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non‐Hodgkin lymphoma and mantle cell lymphoma
Author(s) -
O’Connor Owen A.,
Portlock Carol,
Moskowitz Craig,
Straus David,
Hamlin Paul,
Stubblefield Michael,
Dumetrescu Otila,
Colevas A. Dimitrios,
Grant Barbara,
Zelenetz Andrew
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07271.x
Subject(s) - ixabepilone , medicine , mantle cell lymphoma , lymphoma , chemotherapy , refractory (planetary science) , gastroenterology , non hodgkin's lymphoma , neutropenia , follicular lymphoma , oncology , surgery , cancer , biology , metastatic breast cancer , astrobiology , breast cancer
Summary The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy‐resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non‐Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m 2 weekly for three of four consecutive weeks. Patients were required to have received ≤4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count >1 × 10 9 /l and a platelet count >50 × 10 9 /l. Dose reductions were allowed. The overall response rate in assessable patients was 27% in this otherwise heavily treated population. One patient with chemotherapy‐refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy‐refractory lymphoma.